Monte Rosa Therapeutics (GLUE) Cash from Investing Activities (2020 - 2026)

Monte Rosa Therapeutics' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$261.0 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 160.4% year-over-year to -$261.0 million in Q1 2026; TTM through Mar 2026 was -$262.6 million, a 69.93% decrease from a year earlier, with the FY2025 full-year figure at -$101.8 million, down 129.09% from the prior year.
• Cash from Investing Activities slipped to -$261.0 million in Q1 2026 per GLUE's latest filing, from -$65.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $38.1 million in Q3 2025 and bottomed at -$261.0 million in Q1 2026.
• The 5-year median for Cash from Investing Activities is $9.9 million (2024), against an average of -$31.6 million.
• Biggest YoY gain for Cash from Investing Activities was 1846.98% in 2022; the steepest drop was 8042.53% in 2022.
• Year by year, Cash from Investing Activities stood at -$53.9 million in 2022, then surged by 126.51% to $14.3 million in 2023, then sank by 316.1% to -$30.9 million in 2024, then tumbled by 110.6% to -$65.1 million in 2025, then sank by 301.13% to -$261.0 million in 2026.
• Per Business Quant, the three latest GLUE Cash from Investing Activities figures stand at -$261.0 million (Q1 2026), -$65.1 million (Q4 2025), and $38.1 million (Q3 2025).